Franklin Biolabs Launches as New Genetic Medicines CRO, Expanding Services Globally

• Franklin Biolabs, founded by gene therapy pioneer James Wilson, has commenced operations with a team of over 130 experts.

• The company offers a full range of services to the genetic medicines industry, backed by Savanne Life Sciences.

Franklin Biolabs, headquartered in Philadelphia, has officially launched its operations, marking a significant entry into the genetic medicines sector. Founded by Dr. James Wilson, a renowned figure in gene therapy, the organisation is designed to provide comprehensive solutions from discovery through to development and distribution for clients in the global genetic medicines market.

The company brings together a team of over 130 specialists, offering services that include immunology, vector production, next-generation sequencing, bioinformatics, and nonclinical pharmacology and toxicology studies. Its name pays homage to Ben Franklin, an American scientist and inventor. Franklin Biolabs will conduct research for sponsors across various continents, aiming to address severe disorders through innovative treatments.

Dr. Wilson expressed gratitude for the support from Savanne Life Sciences, stating, “As we officially start operations this week with our eyes on growth and momentum, we are incredibly grateful to the Savanne team for their support and optimism in the future of gene therapy.” He highlighted the shared goal of connecting innovative research with the development of transformative therapies for patients facing serious conditions.

Savanne Life Sciences, the backer of Franklin Biolabs, is focused on investing in emerging biotechnology firms. Their team has extensive experience in medical research, having collaborated with leading companies, universities, and research institutions. Mehul Bhatt, Chief Strategy Officer of Savanne, noted, “Our investment in Franklin Biolabs is a strategic one, premised on a shared commitment to redefining the landscape of the global genetic medicines industry.”